Targeting Telomerase Protein-Protein Interactions in Cancer (BEEKMANA_U121AMS)

A feature of tumours is immortality. This is achieved by overriding our natural ageing process. Our DNA has repeating units on the end that protect our DNA code, like the plastic ends of shoelaces, called telomeres. When cells grow and divide the DNA is incompletely copied, shortening the telomeres. As part of a normal ageing process, when the telomeres are shortened too far the DNA unravels, cells can no longer divide, and die. Cancer uses a complex of proteins called telomerase to add telomeres to the end of DNA, giving tumours immortality. 

This project aims to use a new technique, developed in our lab, to design small molecules which can control this protein complex. This chemical biology project will be interdisciplinary, involving training in the computational design and synthesis of peptides and small molecules, the analysis of compounds binding to proteins and their activity in cancer cells. Led by Dr Andrew Beekman and Professor Mark Searcey, there is an opportunity to learn medicinal chemistry, protein biophysics, cellular biology and structural biology, using facilities across the School of Pharmacy and Norwich Research Park. 

Informal enquiries are welcomed: Dr Andrew Beekman ([Email Address Removed]). For more information on the supervisor for this project, please go here: https://people.uea.ac.uk/a_beekman

This is a PhD programme. The start date is 1st September 2021. The mode of study is full time. The studentship length is 3 years. 

Entry requirements: You will have, or expect to obtain a first class, 2(i) or equivalent Honours degree in Chemistry, Biochemistry, Pharmacy or related area.